昆药集团2025年业绩快报：阶段性承压不改长期韧性 持续锚定银发经济赛道

Core Viewpoint - Kunming Pharmaceutical Group Co., Ltd. is undergoing a critical phase of transformation amid complex external environments, leading to a projected revenue of 6.577 billion yuan and a net profit of 350 million yuan for 2025, with a decline in sales scale and gross margin compared to the previous year [1] Group 1: Business Performance - In 2025, the company faces operational pressure due to multiple factors, including accelerated integration in the pharmaceutical retail industry and normalized medical insurance cost control policies [2] - The company acknowledges the challenges it faces and is actively adjusting its business strategies to seek sustainable development solutions [2] Group 2: Industry Context - The traditional Chinese medicine procurement is moving towards normalization and scale, with increased pricing and market share control for existing products, indicating a shift towards a more standardized and intensive development phase in the industry [2] - Industry experts believe that while short-term pressures may arise from procurement policies, long-term benefits will help the company establish a sustainable competitive advantage in a more transparent market environment [3] Group 3: Strategic Focus - The company is focusing on the silver economy, which is supported by national strategies and dual policy and demand dividends, aiming to become a leader in the silver health industry [4] - The company has built a diversified product matrix covering chronic disease management and emotional health, leveraging its established market foundation in the Sanqi industry chain and cardiovascular treatment products [4] - The company is committed to deepening its existing advantages in the silver health sector and steadily expanding its market presence [5]